Finance
Pennies From the Past
May 28, 2025
You’d think two major shocks — AI drama and a tariff scare — would derail the markets. But U.S. stocks have basically responded with a shrug and a yawn. Despite a bumpy few months, the S&P 500 just wrapped up a week of straight wins, lifted by calming trade news and resilient investor sentiment.
Even with Moody’s yanking the U.S.’s final AAA rating late Friday, the market’s mood didn’t crack. Treasury yields jumped, sure, but the broader indexes marched upward. Meanwhile, backroom trade talks between the U.S. and Europe are gaining steam, and Wall Street is crossing its fingers for continued tariff detente.
When DeepSeek sparked fears of AI saturation and investors briefly flinched, the market quickly realized: this wasn’t the death knell, just another internet-era scare story. Giants like Meta doubled down on 2025 data center spending, Microsoft stayed aggressive, and core AI infrastructure stocks never really broke stride.
Companies like Nvidia, Arista, and Constellation Energy — all integral to the AI data backbone — barely registered the panic. Earnings expectations stayed strong. In short, the AI trade didn’t skip a beat. The narrative took a hit, but the fundamentals stayed rock solid.
Presented by Turn Therapeutics
When faced with a deadly infection boasting a 70% fatality rate and no existing cure, Bradley Burnam did what most wouldn’t dare—he created the solution himself. Enter Hexagen: a groundbreaking formula that Burnam personally shepherded through the FDA clearance process for just $24,000. But he didn’t stop there. Building on this success, Burnam expanded the technology, secured two additional FDA clearances, and founded a company that’s rewriting the rules on self-made medical innovation: Turn Therapeutics.
Hexagen isn’t just breaking barriers; it’s healing them. Cleared for acute wound care and atopic dermatitis, this powerhouse formula is now on the brink of a bigger leap. Turn, the company behind Hexagen, is paving the way to expand its applications, proving there’s much more to its potential than meets the eye.
Turn just locked in a game-changing commitment—up to $75M in investment from GEM Global Yield Fund. This private equity boost is tied to the company’s plans to go public, setting the stage for Turn to make bold moves in the market spotlight..2
Turn is rolling out institutional, accredited, and unaccredited investors to participate in their current crowdfunding campaign — but only until January 2025.3
Back in April, a new round of U.S.-China tariffs sparked fears that consumer-facing companies would get crushed. But fast forward a few weeks, and a basket of those same vulnerable names is back in the green — even outperforming broader benchmarks.
Why the comeback? It turns out markets are treating tariffs less like an existential crisis and more like a speed bump. Talks with China are ongoing, and easing tensions have helped chip away at recession concerns. Translation: Wall Street’s not losing sleep over this anymore.
Both AI and consumer stocks faced serious narrative headwinds this year. But instead of derailing the rally, those headlines just... didn’t land. Recession fears are cooling, and the AI buildout remains red-hot. That leaves only two real threats to this market: a collapse in momentum or a full-blown economic slowdown. For now, neither is on the horizon.
Presented by Atombeam
Big tech, small data… Why are industry leaders like NVIDIA, Intel and Ericsson partnering with Atombeam?1 It’s the company reimagining machine communication — and potentially the future of big tech. That’s thanks to Neurpac, Atombeam’s patented software technology that can reduce the size of low-entropy data by an average of 75%.
Lightning fast… Neurpac enables 2-4x more data to be sent faster and more securely over existing networks—no hardware upgrades — just smart, AI-powered software.
To the moon and back… The U.S Space Force and U.S. Air Force have already been on Atombeam’s customer books — and the company’s potential market is still gaining ground. Atombeam is in discussions with multiple companies, ranging from a major packaging brand to an EV enterprise.
$16M has already been invested into the company. You can invest before the round closes in 29 days.2
1 The partnership relationship varies between companies and can include the following: inclusion on a preferred vendor list, invitations to participate in certain forums; listed on the other company's website, and introduction and networking opportunities.
Advertiser's disclosures:
¹ The Company's Formula (Gx-03/Hexagen/Atopx) Has Received 510k Marketing Approval As A Medical Device Indicated For The Management Of Symptoms Related To Atopic Dermatitis/Eczema. The Formula Has Not Received Approval As A Drug For The Treatment Of Eczema Or Onychomycosis.
² A plan to IPO is no guarantee that an actual IPO will occur.
³ Please read the offering circular and related risks at StartEngine’s Turn Therapeutics webpage. This is a paid advertisement for Turn Therapeutics Regulation CF Offering. This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC.
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.
